Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge rates ALXO Bullish with a Setup Score of 67, net conviction 38, actionability 117. How the Setup Score works →
| Total Setup Score | 67 |
|---|---|
| Directional Bias | Bullish |
| Net Conviction | 38 |
| Actionability | 117 (in range) |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. Read full Trend Edge analysis →
| Current Price | $2.00 |
|---|---|
| Market Cap | $275M |
| Float | 94.7M |
| Shares Outstanding | 138.3M |
| Price/Sales (TTM) | 5,085.96 |
| vs. Analyst Target | +130.0% to analyst PT |
| Dividend Rate | None |
| Analyst Target Price | $4.60 (6 analysts) |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2020 | $1.2M | -$45.7M | $107,000 | -$43.5M |
| 2021 | N/A | -$83.5M | -$736,000 | -$83.4M |
| 2022 | N/A | -$123M | -$1.5M | -$127M |
| 2023 | N/A | -$161M | -$836,000 | -$158M |
| 2024 | N/A | -$135M | -$872,000 | -$132M |
| 2025 | N/A | -$102M | N/A | -$99.4M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Sep 2025 | N/A | -$22.1M |
| Dec 2025 | N/A | -$22.8M |
| Mar 2026 | N/A | -$17.9M |
| Jun 2026 | N/A | -$18.0M |
| Insider Ownership | 0.9% |
|---|---|
| Institutional Ownership | 84.6% |
| Short Float | 8.1% |
| % of All Funds Holding | 1.08% |
| Number of Funds Holding | 95 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $2.04 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $1.82 | Medium-term trend |
| Weekly | 80-Week SMA | $1.36 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $5.03 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $1.80 | Near-term monthly trend |
| Monthly | 20-Month SMA | $1.39 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $4.36 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
| Price Level | Type | Volume Ratio | Age |
|---|---|---|---|
| $1.70 | support | 1.54x | 5 months ago |
| $0.60 | support | 1.82x | 11 months ago |
| $3.20 | resistance | 2.29x | 23 months ago |
| $10.60 | resistance | 1.41x | 25 months ago |
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | 0.32% | 0.81% | 52.00% | 26.34% | -13.05% |
| 1 Day | -2.04% | 0.00% | 48.00% | 7.48% | -19.08% |
| 1 Week | -1.16% | -4.73% | 32.00% | 48.12% | -36.64% |
| 2 Weeks | -1.37% | -6.62% | 40.00% | 95.12% | -46.03% |
| 1 Month | -1.72% | -6.45% | 41.67% | 70.73% | -61.37% |
Next earnings: October 25, 2026 (59 days away)
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
| Day | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Monday | 0.29% | 48.4% | 287 |
| Tuesday | 0.05% | 46.7% | 317 |
| Wednesday | 0.07% | 47.3% | 315 |
| Thursday | -0.37% | 47.2% | 307 |
| Friday | 0.03% | 47.7% | 306 |
Institutional holder breakdown coming soon.
Total institutional ownership: 84.6%
Total insider ownership: 0.9%
Founder-led management: Corey Goodman (Executive Chairman)
| Total Filings | 9 |
|---|---|
| Net Value | +$56,765.758 |
| Net Shares Change | 3,255,035 |
| % of Float | 3.4% |
| C-Suite Filings | 8 |
| Clusters Detected | 0 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| GOODMAN COREY S | +$5.0M | 1 | 1 buy | |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER | +$68,334.618 | 3 | 1 buy, 2 sell |
| Pinto Shelly | SVP, FINANCE AND CAO | -$7,598.81 | 3 | 3 sell |
| Wong Shelly | SVP, FINANCE AND CAO | -$3,970.05 | 2 | 2 sell |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2026-08-18 | Wong Shelly | SVP, FINANCE AND CAO | -$1,105.89 | Transaction at $1.93, now +3.6% |
| 2026-08-18 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | -$4,303.9 | Transaction at $1.93, now +3.6% |
| 2026-07-06 | Wong Shelly | SVP, FINANCE AND CAO | -$2,864.16 | Transaction at $2.04, now -2.0% |
| 2025-09-18 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | +$99,353.388 | Transaction at $1.08, now +85.7% |
| 2026-02-04 | GOODMAN COREY S | +$5.0M | Transaction at $1.57, now +27.4% | |
| 2026-03-23 | Lettmann Jason | CHIEF EXECUTIVE OFFICER | -$26,714.87 | Transaction at $2.17, now -7.8% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Alx Oncology Holdings (ALXO) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for ALXO on Trend Edge →